132 related articles for article (PubMed ID: 8851612)
1. Alteration of postantibiotic effect during one dosing interval of tobramycin, simulated in an in vitro pharmacokinetic model.
den Hollander JG; Mouton JW; van Goor MP; Vleggaar FP; Verbrugh HA
Antimicrob Agents Chemother; 1996 Mar; 40(3):784-6. PubMed ID: 8851612
[TBL] [Abstract][Full Text] [Related]
2. Duration and clinical relevance of postantibiotic effect in relation to the dosing interval.
den Hollander JG; Fuursted K; Verbrugh HA; Mouton JW
Antimicrob Agents Chemother; 1998 Apr; 42(4):749-54. PubMed ID: 9559777
[TBL] [Abstract][Full Text] [Related]
3. Impact of pharmacokinetics on the postantibiotic effect exhibited by Pseudomonas aeruginosa following tobramycin exposure: application of an in-vitro model.
Zhu ZY; Li RC
J Antimicrob Chemother; 1998 Jul; 42(1):61-5. PubMed ID: 9700529
[TBL] [Abstract][Full Text] [Related]
4. Postantibiotic effect and postantibiotic sub-minimum inhibitory concentration effect of valnemulin against Staphylococcus aureus isolates from swine and chickens.
Zhao DH; Yu Y; Zhou YF; Shi W; Deng H; Liu YH
Lett Appl Microbiol; 2014 Feb; 58(2):150-5. PubMed ID: 24117872
[TBL] [Abstract][Full Text] [Related]
5. Postantibiotic effect in Pseudomonas aeruginosa following single and multiple aminoglycoside exposures in vitro.
Karlowsky JA; Zhanel GG; Davidson RJ; Hoban DJ
J Antimicrob Chemother; 1994 May; 33(5):937-47. PubMed ID: 8089067
[TBL] [Abstract][Full Text] [Related]
6. In vitro postantibiotic effect and postantibiotic leukocyte enhancement of tobramycin.
Novelli A; Mazzei T; Fallani S; Cassetta MI; Conti S
J Chemother; 1995 Aug; 7(4):355-62. PubMed ID: 8568546
[TBL] [Abstract][Full Text] [Related]
7. The integration of four major determinants of antibiotic action: bactericidal activity, postantibiotic effect, susceptibility, and pharmacokinetics.
Li RC; Zhu ZY
J Chemother; 2002 Dec; 14(6):579-83. PubMed ID: 12583549
[TBL] [Abstract][Full Text] [Related]
8. Antibiotic exposure and its relationship to postantibiotic effect and bactericidal activity: constant versus exponentially decreasing tobramycin concentrations against Pseudomonas aeruginosa.
Li RC; Zhu ZY; Lee SW; Raymond K; Ling JM; Cheng AF
Antimicrob Agents Chemother; 1997 Aug; 41(8):1808-11. PubMed ID: 9257767
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial activity of subinhibitory concentrations of aminoglycosides against Pseudomonas aeruginosa as determined by the killing-curve method and the postantibiotic effect.
Zhanel GG; Karlowsky JA; Hoban DJ; Davidson RJ
Chemotherapy; 1991; 37(2):114-21. PubMed ID: 1903340
[TBL] [Abstract][Full Text] [Related]
10. Postantibiotic effect of aminoglycosides on staphylococci.
Isaksson B; Maller R; Nilsson LE; Nilsson M
J Antimicrob Chemother; 1993 Aug; 32(2):215-22. PubMed ID: 8226423
[TBL] [Abstract][Full Text] [Related]
11. In vitro postantibiotic effects of tomopenem (CS-023) against Staphylococcus aureus and Pseudomonas aeruginosa.
Tomozawa T; Sugihara C; Kakuta M; Sugihara K; Koga T
J Med Microbiol; 2010 Apr; 59(Pt 4):438-441. PubMed ID: 20093378
[TBL] [Abstract][Full Text] [Related]
12. Use of pharmacodynamic parameters to predict efficacy of combination therapy by using fractional inhibitory concentration kinetics.
den Hollander JG; Mouton JW; Verbrugh HA
Antimicrob Agents Chemother; 1998 Apr; 42(4):744-8. PubMed ID: 9559776
[TBL] [Abstract][Full Text] [Related]
13. Kill kinetics and regrowth patterns of Pseudomonas aeruginosa exposed to concentration-time profiles of tobramycin simulating in vivo infusion and bolus dosing.
Wood PJ; Ioannides-Demos LL; Bastone EB; Spicer WJ; McLean AJ
Antimicrob Agents Chemother; 1996 May; 40(5):1321-4. PubMed ID: 8723496
[TBL] [Abstract][Full Text] [Related]
14. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?
Burkhardt O; Lehmann C; Madabushi R; Kumar V; Derendorf H; Welte T
J Antimicrob Chemother; 2006 Oct; 58(4):822-9. PubMed ID: 16885180
[TBL] [Abstract][Full Text] [Related]
15. Variation in postantibiotic effect of clindamycin against clinical isolates of Staphylococcus aureus and implications for dosing of patients with osteomyelitis.
Xue IB; Davey PG; Phillips G
Antimicrob Agents Chemother; 1996 Jun; 40(6):1403-7. PubMed ID: 8726009
[TBL] [Abstract][Full Text] [Related]
16. Once-daily aminoglycoside dosing assessed by MIC reversion time with Pseudomonas aeruginosa.
Karlowsky JA; Zhanel GG; Davidson RJ; Hoban DJ
Antimicrob Agents Chemother; 1994 May; 38(5):1165-8. PubMed ID: 8067757
[TBL] [Abstract][Full Text] [Related]
17. Impact of meropenem in combination with tobramycin in a murine model of Pseudomonas aeruginosa pneumonia.
Louie A; Liu W; Fikes S; Brown D; Drusano GL
Antimicrob Agents Chemother; 2013 Jun; 57(6):2788-92. PubMed ID: 23571540
[TBL] [Abstract][Full Text] [Related]
18. Hyperoxia prolongs the aminoglycoside-induced postantibiotic effect in Pseudomonas aeruginosa.
Park MK; Muhvich KH; Myers RA; Marzella L
Antimicrob Agents Chemother; 1991 Apr; 35(4):691-5. PubMed ID: 1906262
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamics of intermittent- and continuous-infusion cefepime alone and in combination with once-daily tobramycin against Pseudomonas aeruginosa in an in vitro infection model.
Tessier PR; Nicolau DP; Onyeji CO; Nightingale CH
Chemotherapy; 1999; 45(4):284-95. PubMed ID: 10394012
[TBL] [Abstract][Full Text] [Related]
20. Postantibiotic effect of aminoglycosides on gram-negative bacteria evaluated by a new method.
Isaksson B; Nilsson L; Maller R; Sörén L
J Antimicrob Chemother; 1988 Jul; 22(1):23-33. PubMed ID: 3139614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
